CME and CFTC Clash Over On-Chain Perpetual Futures

The Commodity Futures Trading Commission's recent decision to allow blockchain-based perpetual futures products has ignited a fierce battle with the CME Group, the largest derivatives exchange operator in the US. The CME has sued the CFTC, arguing that the regulator is mislabeling these products and misapplying the law. The dispute centers on the fact that perpetual futures, also known as perps, do not have an expiration date, which the CME claims is a key characteristic of traditional futures contracts. The CME alleges that the CFTC's sudden embrace of perps did not consider the potential harm to its long-dated futures products. The regulator's decision has been seen as a significant development in the rapidly growing market for perps, with non-US volume reportedly reaching $60 trillion last year. The CFTC's move has been met with frustration from some quarters, with critics arguing that the regulator is not properly considering the implications of its decision. The CME's lawsuit argues that the CFTC's approval of perps is a diversion from the law and could have significant consequences for the US derivatives market. The case is currently awaiting federal court action, which could have far-reaching implications for the regulation of perps in the US. The CME's chairman, Terry Duffy, has been vocal in his criticism of the CFTC's decision, arguing that the regulator is not following the proper protocol and may not be prepared to enforce its emerging perps policy. The dispute has highlighted the complex and often contentious relationship between regulators and market participants in the derivatives space. As the case progresses, it is likely to have significant implications for the development of the perps market in the US and beyond.